Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib

BACKGROUND: Melanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, there have been no large studies examining the association...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Lancet Oncol
मुख्य लेखकों: Syeda, Mahrukh M, Wiggins, Jennifer M, Corless, Broderick C, Long, Georgina V, Flaherty, Keith T, Schadendorf, Dirk, Nathan, Paul D, Robert, Caroline, Ribas, Antoni, Davies, Michael A, Grob, Jean Jacques, Gasal, Eduard, Squires, Matthew, Marker, Mahtab, Garrett, James, Brase, Jan C, Polsky, David
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2021
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC8034833/
https://ncbi.nlm.nih.gov/pubmed/33587894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30726-9
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन